A fine balance between CCNL1 and TIMP1 contributes to the development of breast cancer cells

Biochemical and Biophysical Research Communications

Volumn 409, Issue 2, 2011, Pages 344-349

  Peng, Li ^a,b   Yanjiao, Ma ^a,b   Ai guo, Wang ^c   Pengtao, Gong ^a   Jianhua, Li ^a   Ju, Yang ^a   Hongsheng, Ouyang ^a   Xichen, Zhang ^a  

^a JILIN UNIVERSITY   (China)

^b HEILONGJIANG BAYI AGRICULTURAL UNIVERSITY   (China)

^c DALIAN MEDICAL UNIVERSITY   (China)

Author keywords

Breast cancer; CCNL1; Gene expression; TIMP1

Indexed keywords

COMPLEMENTARY DNA; CYCLIN L1; CYCLINE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BREAST CANCER; CANCER CELL; CANCER GROWTH; CANCER TISSUE; CELL GROWTH; DNA MICROARRAY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ADULT; BREAST NEOPLASMS; CELL PROLIFERATION; CYCLINS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TUMOR CELLS, CULTURED;

EID: 79957914594     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.05.021     Document Type: Article

References (16)

1. Redon R., Hussenet T., Bour G., Caulee K., Jost B., Muller D., Abecassis J., du Manoir S. Amplicon mapping and transcriptional analysis pinpoint cyclin L as a candidate oncogene in head and neck cancer. Cancer Res. 2002, 62:6211-6217.
2. Dickinson L.A., Edgar A.J., Ehley J., Gottesfeld J.M. Cyclin L is an RS domain protein involved in pre-mRNA splicing. J. Biol. Chem. 2002, 277:25465-25473.
3. Chen H.H., Wang Y.C., Fann M.J. Identification and characterization of the CDK12/cyclin L1 complex involved in alternative splicing regulation. Mol. Cell. Biol. 2006, 26:2736-2745.
4. Chen H.H., Wong Y.H., Geneviere A.M., Fann M.J. CDK13/CDC2L5 interacts with L-type cyclins and regulates alternative splicing. Biochem. Biophys. Res. Commun. 2007, 354:735-740.
5. Sticht C., Hofele C., Flechtenmacher C., Bosch F.X., Freier K., Lichter P., Joos S. Amplification of Cyclin L1 is associated with lymph node metastases in head and neck squamous cell carcinoma (HNSCC). Br. J. Cancer 2005, 92:770-774.
6. Muller D., Millon R., Théobald S., Hussenet T., Wasylyk B., du Manoir S., Abecassis J. Cyclin L1 (CCNL1) gene alterations in human head and neck squamous cell carcinoma. Br. J. Cancer 2006, 94:1041-1044.
7. Lemaitre V., D'Armiento J. Matrix metalloproteinases in development and disease. Birth Defects Res. C Embryo Today 2006, 78:1-10.
8. Baker A.H., Edwards D.R., Murphy G. Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J. Cell Sci. 2002, 115:3719-3727.
9. Westbrook C.A., Gasson J.C., Gerber S.E., Selsted M.E., Golde D.W. Purification and characterization of human T-lymphocyte-derived erythroid-potentiating activity. J. Biol. Chem. 1984, 259:9992-9996.
10. Jensen S.A., Vainer B., Bartels A., Brünner N., Sørensen J.B. Expression of matrix metalloproteinase 9 (MMP-9) and tissue inhibitor of metalloproteinases 1 (TIMP-1) by colorectal cancer cells and adjacent stroma cells-associations with histopathology and patients outcome. Eur. J. Cancer 2010, 46:3233-3242.
11. Inagaki D., Oshima T., Yoshihara K., Tamura S., Kanazawa A., Yamada T., Yamamoto N., Sato T., Shiozawa M., Morinaga S., Akaike M., Fujii S., Numata K., Kunisaki C., Rino Y., Tanaka K., Masuda M., Imada T. Overexpression of tissue inhibitor of metalloproteinase-1 gene correlates with poor outcomes in colorectal cancer. Anticancer Res. 2010, 30:4127-4130.
12. Loyer P., Trembley J.H., Grenet J.A., Busson A., Corlu A., Zhao W., Kocak M., Kidd V.J., Lahti J.M. Characterization of cyclin L1 and L2 interactions with CDK11 and splicing factors: influence of cyclin L isoforms on splice site selection. J. Biol. Chem. 2008, 283:7721-7732.
13. Herrmann A., Fleischer K., Czajkowska H., Müller-Newen G., Becker W. Characterization of cyclin L1 as an immobile component of the splicing factor compartment. J. FASEB 2007, 21:3142-3152.
14. Würtz S.O., Schrohl A.S., Mouridsen H., Brünner N. TIMP-1 as a tumor marker in breast cancer-an update. Acta Oncol. 2008, 47:580-590.
15. Tannukit S., Wen X., Wang H., Paine M.L. TFIP11, CCNL1 and EWSR1 protein-protein interactions, and their nuclear localization. Int. J. Mol. Sci. 2008, 9:1504-1514.
16. Kozak M. A short leader sequence impairs the fidelity of initiation by eukaryotic ribosomes. Gene Expr. 1991, 1:111-115.